(Q47792667)

English

The potential of hyperpolarized 13C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agents.

scientific article published on 25 August 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

The potential of hyperpolarized 13C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agents. (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

Christoffer Laustsen

object named as

Christoffer Laustsen

4

0 references

Michael R. Horsman

object named as

Michael R Horsman

11

0 references

Hans Stødkilde-Jørgensen

10

object named as

Hans Stødkilde-Jørgensen

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

8

object named as

Johan Bussink

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

5

object named as

Ole L Munk

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

author name string

Ane B Iversen

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

Morten Busk

2

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

Lotte B Bertelsen

3

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

Thomas Nielsen

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

Thomas R Wittenborn

7

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

Jasper Lok

9

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

publication date

25 August 2017

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

Acta Oncologica

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

56

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

11

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

1626-1633

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

Disrupting tumour blood vessels

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Combination of vascular disrupting agents and ionizing radiation.

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Assessing responses to cancer therapy using molecular imaging

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Positron emission tomography as an imaging biomarker

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Imaging metabolic heterogeneity in cancer

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

The roles of PET and PET/CT in the diagnosis and management of prostate cancer

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Positron emission tomography: human brain function and biochemistry

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Potential Clinical Roles for Metabolic Imaging with Hyperpolarized [1-(13)C]Pyruvate

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Real-time metabolic imaging

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

FDG-PET reproducibility in tumor-bearing mice: comparing a traditional SUV approach with a tumor-to-brain tissue ratio approach

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1080%2F0284186X.2017.1351622

21 January 2018

Identifiers

10.1080/0284186X.2017.1351622

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/28840759

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47792667&oldid=2153738017"